Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Italian Journal of Pediatrics
Published in: Italian Journal of Pediatrics 2/2014

Open Access 01-12-2014 | Meeting abstract

The prevention of respiratory syncytial virus infection

Authors: L Bollani, M Pozzi

Published in: Italian Journal of Pediatrics | Special Issue 2/2014

Login to get access

Excerpt

Respiratory syncytial virus (RSV) is the most significant cause of acute respiratory tract infections in infants and young children worldwide. RSV accounts for approximately 70% of hospitalizations for bronchiolitis and 40% of pneumonia among infants <1 year of life. …
Literature
1.
Backman K, Piippo-Savolainen E, Ollikainen H, Koskela H, Korppi M: Increased asthma risk and impaired quality of life after bronchiolitis or pneumonia in infancy. Pediatr Pulmonol. 2014, 49: 318-25. 10.1002/ppul.22842.CrossRefPubMed
2.
The IMpact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998, 102 (3 Pt 1): 531-7.CrossRef
3.
Committee on Infectious Diseases from the Academy of Pediatrics: policy statement: Modified Recommendations for use of Palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009, American Academy of Pediatrics, 124 (6): 1694-1701.
4.
Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Cardiac Study Group: Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in congenital heart disease. J Pediatr. 2003, 143: 532-40. 10.1067/S0022-3476(03)00454-2.CrossRefPubMed
5.
Hall CB, Geoffrey A Weinberg, Aaron K Blumkin: Respiratory syncytial virus associated hospitalization among children less than 24 months of age. Pediatrics. 2013, 132: 341-348. 10.1542/peds.2013-0303.CrossRef
6.
Committee on Infectious Diseases and Bronchiolitis Guidelines Committee: Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014, 134: 415-420.CrossRef
7.
Anabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013, 4: CD006602-
Metadata
Title
The prevention of respiratory syncytial virus infection
Authors
L Bollani
M Pozzi
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Italian Journal of Pediatrics / Issue Special Issue 2/2014
Electronic ISSN: 1824-7288
DOI
https://doi.org/10.1186/1824-7288-40-S2-A35

Other articles of this Special Issue 2/2014

Italian Journal of Pediatrics 2/2014 Go to the issue

Meeting abstract

Immune development in late preterm neonates

Meeting abstract

The late preterm in low income

Meeting abstract

Planning of the nursing team in the management of multiple births: from medically assisted reproduction center to neonatal intensive care unit

Meeting abstract

Hypoglycaemia and neonatal brain injury

Meeting abstract

Chorioamnionitis and neonatal outcome: early vs late preterm infants

Meeting abstract

Late preterm infants’ growth and body composition after discharge